envudeucitinib

Envudeucitinib is a highly selective, next-generation oral small molecule inhibitor of Tyrosine kinase 2 (TYK2), developed initially by Fronthera U.S. Pharmaceuticals and now owned by Alumis. Inc. It is designed to target the TYK2 signaling pathway that regulates key pro-inflammatory cytokines including IL-12, IL-23, and type I interferons. Its main therapeutic focus is autoimmune diseases such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, aiming to reduce inflammation and improve symptoms by selectively inhibiting TYK2. Clinical studies emphasize its oral dosing and anti-inflammatory properties.[1][2][3][6][7]

Brand names

envudeucitinib

Other names

envudeucitinibumenvu